{"filing":{"accession_number":"0001213900-26-078316","cik":"0001611746","ticker":"SPRC","company_name":"SciSparc Ltd.","form":"6-K","filing_date":"2026-07-15","report_date":null,"primary_document":"ea0298095-6k_scisparc.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1611746/000121390026078316/ea0298095-6k_scisparc.htm"},"events":[{"id":18119,"run_id":16273,"accession_number":"0001213900-26-078316","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces the initiation of a Phase IIb clinical trial for SCI-110 at Hannover Medical School in Germany, representing a material advancement in SciSparc's drug development pipeline for Tourette Syndrome. The disclosure describes a significant operational and clinical milestone—progression from Phase IIa to Phase IIb with positive prior safety and efficacy data (21% average tic reduction)—that would affect a reasonable investor's assessment of the company's pipeline progress and commercial prospects, but does not fit the discrete event categories of earnings release, M\u0026A, executive changes, or other named types.","company_name":"SciSparc Ltd.","ticker":"SPRC","filing_date":"2026-07-15","form":"6-K","submitted_at":null,"items":[{"id":16831,"accession_number":"0001213900-26-078316","item_number":"EX-99.1","item_title":"ea029809502ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces the initiation of a Phase IIb clinical trial for SCI-110 at Hannover Medical School in Germany, representing a material advancement in SciSparc's drug development pipeline for Tourette Syndrome. The disclosure describes a significant operational and clinical milestone—progression from Phase IIa to Phase IIb with positive prior safety and efficacy data (21% average tic reduction)—that would affect a reasonable investor's assessment of the company's pipeline progress and commercial prospects, but does not fit the discrete event categories of earnings release, M\u0026A, executive changes, or other named types.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:04:02.217826+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16831,"accession_number":"0001213900-26-078316","item_number":"EX-99.1","item_title":"ea029809502ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces the initiation of a Phase IIb clinical trial for SCI-110 at Hannover Medical School in Germany, representing a material advancement in SciSparc's drug development pipeline for Tourette Syndrome. The disclosure describes a significant operational and clinical milestone—progression from Phase IIa to Phase IIb with positive prior safety and efficacy data (21% average tic reduction)—that would affect a reasonable investor's assessment of the company's pipeline progress and commercial prospects, but does not fit the discrete event categories of earnings release, M\u0026A, executive changes, or other named types.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:04:02.217826+00:00","company_name":"SciSparc Ltd.","ticker":"SPRC","filing_date":"2026-07-15"}]}